Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6190522 | Cancer Treatment Reviews | 2014 | 7 Pages |
Abstract
These data confirm the limited effectiveness of currently available palliative chemotherapy regimens for RMSCCHN patients. Novel therapeutics offering improvements in quality and quantity of life are urgently needed for these patients. Based on these results, the study of such agents as first-line therapy in RMSCCHN patients is entirely justifiable.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Eric Winquist, Intisar Al-Rasheedy, Anthony C. Nichols, David A. Palma, Larry Stitt,